TABLE 1.
Characteristics of colorectal cancer patients by the status of p53 Mutation based on gain of function classification (N = 286).
| TP53 WT (n = 90) | TP53 Mut (n = 196) | p Value | TP53 non‐GOF Mut (n = 65) | TP53 GOF Mut (n = 131) | p Value | |
|---|---|---|---|---|---|---|
| Sex | 0.351 | 0.409 | ||||
| Male | 51 (56.67%) | 124 (63.27%) | 38 (58.46%) | 86 (65.65%) | ||
| Female | 39 (43.33%) | 72 (36.73%) | 27 (41.54%) | 45 (34.35%) | ||
| Onset | 0.154 | 0.561 | ||||
| Early onset | 27 (30.00%) | 42 (21.43%) | 16 (24.62%) | 26 (19.85%) | ||
| Late onset | 63 (70.00%) | 154 (78.57%) | 49 (75.38%) | 105 (80.15%) | ||
| Sidedness | 0.035 | 0.682 | ||||
| Left‐sided | 60 (66.67%) | 155 (79.08%) | 53 (81.54%) | 102 (77.86%) | ||
| Right‐sided | 30 (33.33%) | 41 (20.92%) | 12 (18.46%) | 29 (22.14%) | ||
| Stage | 0.094 | 0.543 | ||||
| III | 47 (52.22%) | 80 (40.82%) | 29 (44.62%) | 51 (38.93%) | ||
| IV | 43 (47.78%) | 116 (59.18%) | 36 (55.38%) | 80 (61.07%) | ||
| KRAS | 0.252 | 0.917 | ||||
| WT | 40 (44.44%) | 103 (52.55%) | 35 (53.85%) | 68 (51.91%) | ||
| Mut | 50 (55.56%) | 93 (47.45%) | 30 (46.15%) | 63 (48. 09%) | ||
| BRAF | 0.541 | 0.730 | ||||
| WT | 81 (90.00%) | 183 (93.37%) | 61 (93.85%) | 122 (93.13%) | ||
| V600E mut | 5 (5.56%) | 7 (3.57%) | 3 (4.61%) | 4 (3.05%) | ||
| Other mut | 4 (4.44%) | 6 (3.06%) | 1 (1.54%) | 5 (3.82) | ||
| MSI/MMR | 0.010 | 1.000 | ||||
| MSI‐H/dMMR | 10 (11.11%) | 5 (2.55%) | 2 (3.08%) | 3 (2.29%) | ||
| MSS/pMMR | 72 (80.00%) | 177 (90.31%) | 59 (90.77%) | 118 (90.08%) | ||
| Unknown | 8 (8.89%) | 14 (7.14%) | 4 (6.15) | 10 (7.63%) | ||
| Surgery for primary lesion | 0.574 | 0.215 | ||||
| No | 23 (25.56%) | 58 (29.59%) | 15 (23.08%) | 43 (32.82%) | ||
| Yes | 67 (74.44%) | 138 (70.41%) | 50 (76.92%) | 88 (67.18%) | ||
| Targeted therapy | 0.853 | 0.387 | ||||
| No | 38 (42.22%) | 82 (41.84%) | 24 (36.92%) | 58 (44.28%) | ||
| Anti‐VEGF/VEGFR | 26 (28.89%) | 61 (31.12%) | 23 (35.38%) | 38 (29.01%) | ||
| Anti‐EGFR | 8 (8.89%) | 20 (10.21%) | 7 (10.77%) | 13 (9.92%) | ||
| Anti‐VEGF/VEGFR + anti‐EGFR | 7 (7.78%) | 17 (8.67%) | 8 (12.31%) | 9 (6.87%) | ||
| Yes (specific drugs unknown) | 11 (12.22%) | 16 (8.16%) | 3 (4.62%) | 13 (9.92%) | ||
| Chemotherapy | 1.000 | 0.400 | ||||
| No | 3 (3.33%) | 6 (3.06%) | 3 (4.62%) | 3 (2.29%) | ||
| Yes | 87 (96.67%) | 190 (96.94%) | 62 (95.38%) | 128 (97.71%) | ||
Abbreviations: CRC, colorectal cancer; dMMR, deficient mismatch repair; GOF, gain of function; MSI‐H, high microsatellite instability level; MSS, microsatellite stable; pMMR, proficient mismatch repair; WT, wild‐type.